Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer

被引：8

作者：

Zhu, Jason ^{[1
]}

Tucker, Matthew ^{[2
]}

Wang, Endi ^{[3
]}

Grossman, Joel S. ^{[4
]}

Armstrong, Andrew J. ^{[1
]}

George, Daniel J. ^{[1
]}

Zhang, Tian ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol,Duke Canc Inst, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

[3] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA

[4] Florida Canc Specialists & Res Inst, Naples, FL USA

来源：

CLINICAL GENITOURINARY CANCER | 2017年 / 15卷 / 06期

关键词：

Adverse events; DNA repair; PARP inhibitors; Secondary malignancy; Treatment-related leukemia; BRCA MUTATION CARRIERS; BREAST-CANCER; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; ADVANCED OVARIAN; PARP INHIBITORS; THERAPY; CHEMOTHERAPY; RADIOTHERAPY; MAINTENANCE;

D O I：

10.1016/j.clgc.2017.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer is the third most common cause of cancer-related deaths among men in the United States. Twenty-five percent to 30% of sporadic castration-resistant prostate cancers are characterized by defects in DNA repair. Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors exploit defects in DNA repair to induce tumor-selective cytotoxicity and are in clinical development for treatment of prostate cancer. Serious adverse events might occur after the use of a PARP inhibitor for patients with metastatic castrationresistant prostate cancer. Long-term safety monitoring will be a necessary end point in evaluating the clinical benefit of PARP inhibitors in patients with genetically susceptible tumors.

引用

页码：E1137 / E1141

页数：5

共 23 条

[1]

Brenner DJ, 2000, CANCER, V88, P398, DOI 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO

[2]

2-V

[3] Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia [J].

Churpek, Jane E. ;

Marquez, Rafael ;

Neistadt, Barbara ;

Claussen, Kimberly ;

Lee, Ming K. ;

Churpek, Matthew M. ;

Huo, Dezheng ;

Weiner, Howard ;

Bannerjee, Mekhala ;

Godley, Lucy A. ;

Le Beau, Michelle M. ;

Pritchard, Colin C. ;

Walsh, Tom ;

King, Mary-Claire ;

Olopade, Olufunmilayo I. ;

Larson, Richard A. .

CANCER, 2016, 122 (02) :304-311

[4] Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer [J].

Drew, Yvette ;

Ledermann, Jonathan ;

Hall, Geoff ;

Rea, Daniel ;

Glasspool, Ros ;

Highley, Martin ;

Jayson, Gordon ;

Sludden, Julieann ;

Murray, James ;

Jamieson, David ;

Halford, Sarah ;

Acton, Gary ;

Backholer, Zoe ;

Mangano, Raffaella ;

Boddy, Alan ;

Curtin, Nicola ;

Plummer, Ruth .

BRITISH JOURNAL OF CANCER, 2016, 114 (07) :723-730

[5] PALB2 Mutations and Breast-Cancer Risk [J].

Evans, Michele K. ;

Longo, Dan L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (06) :566-568

[6] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].

Fong, Peter C. ;

Boss, David S. ;

Yap, Timothy A. ;

Tutt, Andrew ;

Wu, Peijun ;

Mergui-Roelvink, Marja ;

Mortimer, Peter ;

Swaisland, Helen ;

Lau, Alan ;

O'Connor, Mark J. ;

Ashworth, Alan ;

Carmichael, James ;

Kaye, Stan B. ;

Schellens, Jan H. M. ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134

[7] The mutational landscape of lethal castration-resistant prostate cancer [J].

Grasso, Catherine S. ;

Wu, Yi-Mi ;

Robinson, Dan R. ;

Cao, Xuhong ;

Dhanasekaran, Saravana M. ;

Khan, Amjad P. ;

Quist, Michael J. ;

Jing, Xiaojun ;

Lonigro, Robert J. ;

Brenner, J. Chad ;

Asangani, Irfan A. ;

Ateeq, Bushra ;

Chun, Sang Y. ;

Siddiqui, Javed ;

Sam, Lee ;

Anstett, Matt ;

Mehra, Rohit ;

Prensner, John R. ;

Palanisamy, Nallasivam ;

Ryslik, Gregory A. ;

Vandin, Fabio ;

Raphael, Benjamin J. ;

Kunju, Lakshmi P. ;

Rhodes, Daniel R. ;

Pienta, Kenneth J. ;

Chinnaiyan, Arul M. ;

Tomlins, Scott A. .

NATURE, 2012, 487 (7406) :239-243

[8] The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability [J].

Gudmundsdottir, K. ;

Ashworth, A. .

ONCOGENE, 2006, 25 (43) :5864-5874

[9] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].

Kaufman, Bella ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Steiner, Mariana ;

Loman, Niklas ;

Bowen, Karin ;

Fielding, Anitra ;

Domchek, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250

[10] FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy [J].

Kim, Geoffrey ;

Ison, Gwynn ;

Mckee, Amy E. ;

Zhang, Hui ;

Tang, Shenghui ;

Gwise, Thomas ;

Sridhara, Rajeshwari ;

Lee, Eunice ;

Tzou, Abraham ;

Philip, Reena ;

Chiu, Haw-Jyh ;

Ricks, Tiffany K. ;

Palmby, Todd ;

Russell, Anne Marie ;

Ladouceur, Gaetan ;

Pfuma, Elimika ;

Li, Hongshan ;

Zhao, Liang ;

Liu, Qi ;

Venugopal, Rajesh ;

Ibrahim, Amna ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2015, 21 (19) :4257-4261

← 1 2 3 →